# Tolerance by Engaging Antigen During Cellular Homeostasis

> **NCT03504241** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 8 (actual)

## Conditions studied

- Kidney Transplantation
- Renal Transplantation
- Renal Transplant Recipient

## Interventions

- **BIOLOGICAL:** Donor-derived Mesenchymal Stromal Cells
- **DRUG:** alemtuzumab
- **DRUG:** belatacept
- **DRUG:** sirolimus
- **DRUG:** mycophenolate mofetil
- **DRUG:** mycophenolate acid
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT03504241
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-30
- **Primary completion:** 2023-09-06
- **Final completion:** 2025-09-16
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03504241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03504241, "Tolerance by Engaging Antigen During Cellular Homeostasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03504241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*